BIOGEN INC. — Director's Dealing 2023

Apr 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2023-03-31

Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-31	Common Stock	M	239	—	Acquired	5818.2903	Direct
2023-03-31	Common Stock	F	116	$278.03	Disposed	5702.2903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-31	Restricted Stock Unit	$0	M	239	Disposed	2024-04-01	Common Stock (239)	Direct

Footnotes

F1: Includes 91.6992 shares acquired under the Biogen Inc. employee stock purchase plan.

F2: This award was granted to the reporting person on April 1, 2021. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date.